Cognito TX
Cambridge, US Β· Founded 2016 Β· 69 employees on LinkedIn Β· 2 known investors
Cognito Therapeutics develops Spectris, a non-invasive sensory stimulation technology platform to treat neurodegenerative diseases including Alzheimer's by improving cognitive performance. The company serves patients with neurodegenerative conditions and aims to transform disease management through clinical-to-commercial pathways in the neurological therapeutics sector.
Founders & leadership
Cognito TX was founded in 2016 by Ed Boyden and Li-Huei Tsai.
Investors Β· 2
Competitors Β· 5
by search overlap
Cognition Therapeutics30 shared keywordsCognition Therapeutics is a clinical-stage biotechnology company developing zervimesine (CT1812), an investigational once-daily oral small-molecule therapy designed to protect brain synapses by blocking toxic protein oligomers. It targets neurodegenerative diseases including dementia with Lewy bodies (DLB) and Alzheimer's disease.
Cognision26 shared keywordsCognision develops an objective measurement system for evaluating patients with cognitive disorders including concussion, mTBI, and dementia, serving clinicians, pharmaceutical companies, and researchers through brain-based biomarkers and qEEG/ERP testing.
Bioworld20 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Cognixion18 shared keywordsCognixion develops non-invasive brain-computer interfaces and adaptive assistive technology that provide communication and control for people with complex disabilities. Its multimodal systems combine intent, context, and accessible spatial computing across interfaces such as the Apple Vision Pro.
Cognigenics16 shared keywordsCognigenics is developing iRNAi, a non-invasive intranasal RNA interference platform that delivers programmable RNA therapeutics directly to targeted brain circuits, bypassing the blood-brain barrier to modulate mood, memory, and cognition. The company focuses on precision neuropsychiatry and treatments for neurological and psychiatric disorders.
Companies competing with Cognito TX for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Cognito TX do?
- Cognito Therapeutics develops Spectris, a non-invasive sensory stimulation technology platform to treat neurodegenerative diseases including Alzheimer's by improving cognitive performance. The company serves patients with neurodegenerative conditions and aims to transform disease management through clinical-to-commercial pathways in the neurological therapeutics sector.
- Who founded Cognito TX?
- Cognito TX was founded by Ed Boyden, Li-Huei Tsai in 2016.
- Who are Cognito TX's investors?
- Cognito TX's investors include FoundersX Ventures, OPAMP CAPITAL.
- Where is Cognito TX headquartered?
- Cognito TX is headquartered in Cambridge, US.